Recent news primarily covers Cannabis Suisse Corp.'s product development and business activities up to 2021, with no recent business-specific news in 2026. The company has announced multiple CBD product launches, IT product development, and distribution agreements.

• Cannabis Suisse Corp. reported year results for 2021, highlighting its financial position and business activities [N7].
• The company announced the design of a new IT product 'Cannabis Life' based on artificial intelligence in November 2021 [N8].
• Cannabis Suisse Corp. has launched multiple CBD products under its Swiss4Life brand, including pre-rolled cannabis joints and cannabis oils, with laboratory testing conducted by ACS Laboratory [N7].
• The company has engaged ShipBob as a fulfillment center to support its distribution operations [N7].
• Cannabis Suisse Corp. has announced distribution negotiations and agreements to expand its market reach [N7].

Cannabis Suisse Corp. has developed a portfolio of CBD products under the Swiss4Life brand and is advancing an AI-based IT product, 'Cannabis Life', which could provide new business avenues. The company has established partnerships for product testing and fulfillment, indicating operational progress. Its net income reported in the latest fiscal year, despite zero revenue, suggests some financial management or non-operating income. The CEO’s control may enable swift decision-making and strategic direction.

The company has very limited operations, no employees, and relies heavily on its CEO for funding and management, which poses operational risks. The going concern opinion and very low liquidity ratios highlight significant financial distress and uncertainty about continued operations. The lack of revenue and dependence on subleasing income limit business sustainability. The penny stock status and related trading restrictions may hinder capital raising and liquidity. Concentrated voting control raises governance risks.

Cannabis Suisse Corp. operates in the CBD and cannabis-related product sector, which is competitive and subject to regulatory and market challenges. The company’s limited operations, lack of employees, and reliance on a single individual for management reduce its operational scale and potential competitive advantages. Its product development efforts, including the AI-based 'Cannabis Life' IT product and Swiss4Life CBD brand, represent attempts to differentiate, but the company’s small scale and financial constraints limit its moat.

• Limited Operations and Business Model Uncertainty: The company’s current operations are limited to subleasing part of a building, with no assurance of sustainable business activities covering costs.
• Liquidity and Going Concern Risk: Cannabis Suisse Corp. has a going concern opinion in its latest audited financials, indicating substantial doubt about its ability to continue without additional capital.
• Management and Personnel Constraints: The company has no employees and relies on its CEO, who also serves as CFO part-time, limiting its capacity to develop and grow the business.
• Concentrated Voting Control: The CEO holds majority voting power and convertible notes convertible into a large number of shares, concentrating control and potentially affecting governance.
• Penny Stock and Liquidity Risks: The company’s shares are classified as penny stocks, subject to trading restrictions and limited market maker interest, which may reduce liquidity and increase price volatility.

• Cannabis Suisse Corp. currently has limited operations consisting mainly of subleasing a portion of a building leased from a company controlled by its CEO.
• The company has no employees; the CEO also serves as CFO on a part-time consultant basis, which limits its operational capacity.
• The CEO holds a majority of the voting stock and controls the board and business decisions, including convertible promissory notes convertible into over 135 million shares as of May 31, 2026.
• The company has a 'going concern' opinion in its audited financial statements as of May 31, 2026, indicating substantial doubt about its ability to continue without additional capital.
• As of May 31, 2026, Cannabis Suisse Corp. reported cash and equivalents of $476, current assets of $53,187, and current liabilities of $565,399, resulting in a current ratio of 0.09 and a cash ratio of 0.
• The company reported net income of $122,739 for the fiscal year ended May 31, 2026, with zero reported revenue for the same period.
• Cannabis Suisse Corp. has developed and announced multiple CBD product lines under its Swiss4Life brand, including pre-rolled cannabis joints and cannabis oils.
• The company has engaged ACS Laboratory for CBD potency testing and ShipBob as a fulfillment center.
• Cannabis Suisse Corp. has announced the development of an IT product called 'Cannabis Life' based on artificial intelligence, with multiple press releases detailing its progress.
• The company has announced distribution agreements and expansion plans for online sales, including using Shopify as a platform.
• The company’s shares are classified as penny stocks, subject to related trading restrictions and liquidity challenges.